title: Percutaneous computed tomography-guided iodine-125 seeds implantation for unresectable pancreatic cancer.
abstract: BACKGROUND
  To examine the safety and clinical efficacy of computed tomography (CT)-guided radioactive iodine-125 (125I) seeds implantation for patients with unresectable pancreatic cancer.
  
  
  METHODS
  A group of 26 patients with pathologically confirmed unresectable pancreatic cancer underwent percutaneous CT-guided 125I seeds implantation. Part of them received transarterial chemotherapy and/or percutaneous transhepatic cholangial drainage before or after seeds implantation. The primary endpoints were the objective response rates, local control rates, and overall survival.
  
  
  RESULTS
  CT scan 2 months after treatment revealed complete response (CR) in 8 patients, partial response (PR) in 9 patients. Overall response rate (CR + PR) is 65.38%. Local control rate was 88.46%. Median survival of the whole group was 15.3 months, whereas for Stage III and IV was 17.6 and 9.1 months, respectively. The estimated 1-year survival was 30.77%.
  
  
  CONCLUSIONS
  We consider CT-guided 125I seeds implantation as a safe, effective, uncomplicated treatment for unresectable pancreatic cancer.
authors.forename: B
authors.initials: B
authors.lastname: Liu
authors.forename: T
authors.initials: T
authors.lastname: Zhou
authors.forename: J
authors.initials: J
authors.lastname: Geng
authors.forename: F
authors.initials: F
authors.lastname: Zhang
authors.forename: J
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Interventional Medicine, The Second Hospital of Shandong University, Shandong, Shandong Province, PR of, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Li
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy*; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy; D021441:Carcinoma, Pancreatic Ductal / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy*; D018279:Carcinoma, Signet Ring Cell / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy*; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009366:Neoplasm Seeding; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy*; D011379:Prognosis; D061089:Radiotherapy, Image-Guided / Q000379:methods*; D015996:Survival Rate; D014057:Tomography, X-Ray Computed / Q000379:methods*
chemical_list: D007457:Iodine Radioisotopes